Hypofractionated Radiation — Accelerated Radiotherapy Schedules

Hypofractionated radiation therapy is an advanced treatment regimen where the total planned dose of radiation is divided into fewer, larger fractions. Standard or conventionally fractionated radiotherapy typically delivers small doses of approximately 1.8 to 2 Gray (Gy) once daily over five to seven weeks. In contrast, hypofractionation delivers higher individual doses, often exceeding 2.5 Gy per session, completing the entire course in one to three weeks.

This technique relies on modern computerised treatment planning and precise beam delivery to ensure that the surrounding healthy tissues receive minimal exposure despite the higher per-fraction dose. Hypofractionation can be moderate (completed over a few weeks) or ultra-hypofractionated, often referred to as stereotactic body radiotherapy (SBRT), which finishes in one to five fractions.

Completing radiation in fewer sessions dramatically reduces logistical, financial, and emotional strain. Patients spend less time travelling, take fewer days off work, and face fewer disruptions to family commitments. Clinically, large clinical trials have demonstrated that hypofractionation provides tumour control rates and safety profiles equivalent to traditional schedules for appropriate candidates, allowing patients to complete their cancer care and return to routine life much sooner.

Suitability is determined through pre-treatment anatomical imaging rather than laboratory biomarkers. High-resolution computed tomography (CT) scans, magnetic resonance imaging (MRI), and sometimes positron emission tomography (PET) scans are used to map tumour boundaries and ensure nearby organs at risk can safely tolerate the higher per-fraction doses.

Hypofractionated radiotherapy has become a standard approach in early-stage breast cancer following breast-conserving surgery. It is also widely used in localised prostate cancer, non-small cell lung cancer, bone metastases, and select cases of rectal, brain, and pancreatic cancers.

This radiotherapy modality is often integrated alongside surgical resection, systemic chemotherapy, or endocrine therapy. Because treatment finishes faster, hypofractionation can minimise delays when sequencing other therapies, such as adjuvant chemotherapy or targeted treatments, allowing clinical schedules to run smoothly without unnecessary breaks in care.